Artificial intelligence company Atomwise is applying deep learning technology to drug discovery, allowing it to find promising molecules for diseases once considered ‘undruggable’. Following its recent $123m Series B funding round, Abi Millar profiles the growth of the company and finds out what’s in store for 2021 and beyond.
US-based Atomwise is leading the charge in applying artificial intelligence to drug discovery. Since the company was founded in 2012, its platform, AtomNet, has identified a slew of drug candidates for supposedly ‘undruggable’ targets. The company has an extensive range of partnerships with big pharma and small biotechs, along with a number of spin-off companies.
In August, the company announced it had raised $123m in Series B funding, which will be used to scale up all its activities, including its own drug development pipeline. Atomwise CEO and co-founder Abraham Heifets discusses how artificial intelligence is changing the face of drug discovery.
Read the rest of this article in the November 2020 edition of Pharma Technology Focus